163 related articles for article (PubMed ID: 35930755)
1. AZD4625 is a Potent and Selective Inhibitor of KRASG12C.
Chakraborty A; Hanson L; Robinson D; Lewis H; Bickerton S; Davies M; Polanski R; Whiteley R; Koers A; Atkinson J; Baker T; Del Barco Barrantes I; Ciotta G; Kettle JG; Magiera L; Martins CP; Peter A; Wigmore E; Underwood Z; Cosulich S; Niedbala M; Ross S
Mol Cancer Ther; 2022 Oct; 21(10):1535-1546. PubMed ID: 35930755
[TBL] [Abstract][Full Text] [Related]
2. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura S; Mzannar Y; Azar I; Beal E; Tobon M; Kim S; Beydoun R; Baloglu E; Senapedis W; El-Rayes B; Philip PA; Mohammad RM; Shields AF; Al-Hallak MN; Azmi AS
bioRxiv; 2023 Mar; ():. PubMed ID: 37034616
[TBL] [Abstract][Full Text] [Related]
3. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A; Lorthiois E; Barys L; Beyer KS; Bomio-Confaglia C; Burks H; Chen X; Cui X; de Kanter R; Dharmarajan L; Fedele C; Gerspacher M; Guthy DA; Head V; Jaeger A; Núñez EJ; Kearns JD; Leblanc C; Maira SM; Murphy J; Oakman H; Ostermann N; Ottl J; Rigollier P; Roman D; Schnell C; Sedrani R; Shimizu T; Stringer R; Vaupel A; Voshol H; Wessels P; Widmer T; Wilcken R; Xu K; Zecri F; Farago AF; Cotesta S; Brachmann SM
Cancer Discov; 2022 Jun; 12(6):1500-1517. PubMed ID: 35404998
[TBL] [Abstract][Full Text] [Related]
4. Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS
Kettle JG; Bagal SK; Bickerton S; Bodnarchuk MS; Boyd S; Breed J; Carbajo RJ; Cassar DJ; Chakraborty A; Cosulich S; Cumming I; Davies M; Davies NL; Eatherton A; Evans L; Feron L; Fillery S; Gleave ES; Goldberg FW; Hanson L; Harlfinger S; Howard M; Howells R; Jackson A; Kemmitt P; Lamont G; Lamont S; Lewis HJ; Liu L; Niedbala MJ; Phillips C; Polanski R; Raubo P; Robb G; Robinson DM; Ross S; Sanders MG; Tonge M; Whiteley R; Wilkinson S; Yang J; Zhang W
J Med Chem; 2022 May; 65(9):6940-6952. PubMed ID: 35471939
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
7. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB
Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605
[TBL] [Abstract][Full Text] [Related]
8. KRASG12C inhibitor: combing for combination.
Chakraborty A
Biochem Soc Trans; 2020 Dec; 48(6):2691-2701. PubMed ID: 33242077
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue.
Chambers AG; Chain DC; Sweet SM; Song Z; Martin PL; Ellis MJ; Rooney C; Kim YJ
Clin Proteomics; 2023 Oct; 20(1):47. PubMed ID: 37880622
[TBL] [Abstract][Full Text] [Related]
10. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
11. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
12. Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.
Post JB; Roodhart JML; Snippert HJG
Trends Cancer; 2020 Feb; 6(2):111-129. PubMed ID: 32061302
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
Sini P; Gürtler U; Zahn SK; Baumann C; Rudolph D; Baumgartinger R; Strauss E; Haslinger C; Tontsch-Grunt U; Waizenegger IC; Solca F; Bader G; Zoephel A; Treu M; Reiser U; Garin-Chesa P; Boehmelt G; Kraut N; Quant J; Adolf GR
Mol Cancer Ther; 2016 Oct; 15(10):2388-2398. PubMed ID: 27496137
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
15. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.
Jia Y; Juarez J; Li J; Manuia M; Niederst MJ; Tompkins C; Timple N; Vaillancourt MT; Pferdekamper AC; Lockerman EL; Li C; Anderson J; Costa C; Liao D; Murphy E; DiDonato M; Bursulaya B; Lelais G; Barretina J; McNeill M; Epple R; Marsilje TH; Pathan N; Engelman JA; Michellys PY; McNamara P; Harris J; Bender S; Kasibhatla S
Cancer Res; 2016 Mar; 76(6):1591-602. PubMed ID: 26825170
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
17. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
19. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
20. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]